Predictive Markers for Response to Immunosuppressive Therapy in Aplastic Anaemia

Area of Science:

• Hematology
• Immunology
• Genetics

Background:

• Aplastic anemia (AA) is a rare, life-threatening bone marrow failure disorder.
• Current treatments include hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST), each with limitations.
• Personalized treatment strategies are needed due to varying IST efficacy and risks of relapse or transformation.

Purpose of the Study:

• To review clinical, immunological, and genetic markers that predict response to IST in AA patients.
• To highlight the need for validated predictive markers for personalized treatment and improved outcomes.

Main Methods:

• Literature review of studies identifying potential predictive markers for IST response in AA.
• Focus on clinical, immunological (e.g., cytokine levels), and genetic markers (e.g., telomere length, PNH clone size).

Main Results:

• Several markers, including cytokine levels, telomere length, and PNH clone size, show potential for predicting IST response.
• Current evidence is largely from retrospective studies with methodological inconsistencies.
• Limited reproducibility hinders clinical implementation of these markers.

Conclusions:

• Validated predictive markers are essential for personalizing IST in AA.
• Standardized, large-scale prospective studies are required to confirm marker utility.
• Developing a scoring system integrating clinical and molecular data could enhance AA management and patient outcomes.